Trials / Sponsors / Canadian Myeloma Research Group
Canadian Myeloma Research Group
Academic / Other · 6 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients Multiple Myeloma | Phase 2 | 2024-12-12 |
| Active Not Recruiting | A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM Multiple Myeloma | Phase 2 | 2021-12-08 |
| Withdrawn | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamet Multiple Myeloma | Phase 2 | 2021-02-17 |
| Completed | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myelo Multiple Myeloma in Relapse | Phase 2 | 2018-12-03 |
| Active Not Recruiting | Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex Relapsed and/or Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2018-11-26 |
| Completed | A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide Multiple Myeloma | Phase 2 | 2017-10-25 |